Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease
Identifieur interne : 002A28 ( PascalFrancis/Checkpoint ); précédent : 002A27; suivant : 002A29Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease
Auteurs : Alberto Albanese [Italie] ; Ubaldo Bonuccelli [Italie] ; Christine Brefel [France] ; K. Ray Chaudhuri [Royaume-Uni] ; Carlo Colosimo [Italie] ; Tobias Eichhorn [Allemagne] ; Eldad Melamed [Israël] ; Pierre Pollak [France] ; Teus Van Laar [Pays-Bas] ; Mario Zappia [Italie]Source :
- Movement disorders [ 0885-3185 ] ; 2001.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Recommandation, Homme.
English descriptors
- KwdEn :
Abstract
Available evidence on the practice of acute pharmacological challenge tests in parkinsonian patients was reviewed by a committee of experts, which achieved a general consensus. The published data deal mainly with the acute administration of levodopa and apomorphine in Parkinson's disease. Such challenge may serve different purposes, e.g., research, diagnosis, or tailoring of treatment. Unique protocols describing the clinical setting and practice parameters are not available. The present paper describes the scientific background and supplies practical guidelines, whenever possible, to perform and evaluate acute challenge tests in parkinsonian syndromes. With the appropriate indication and setting, acute challenge tests are useful in diagnosis and therapy of Parkinson's disease and related disorders.
Affiliations:
- Allemagne, France, Israël, Italie, Pays-Bas, Royaume-Uni
- Angleterre, Auvergne-Rhône-Alpes, Grand Londres, Hollande-Méridionale, Latium, Rhône-Alpes
- Grenoble, Leyde, Londres, Rome, Toulouse
- Centre hospitalier universitaire Grenoble Alpes, Université de Rome « La Sapienza »
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:01-0333009Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease</title><author><name sortKey="Albanese, Alberto" sort="Albanese, Alberto" uniqKey="Albanese A" first="Alberto" last="Albanese">Alberto Albanese</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Istituto di Neurologia, Università Cattolica, and Istituto Nazionale Neurologico</s1><s2>Milano</s2><s3>ITA</s3><sZ>1 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Milano</wicri:noRegion></affiliation></author><author><name sortKey="Bonuccelli, Ubaldo" sort="Bonuccelli, Ubaldo" uniqKey="Bonuccelli U" first="Ubaldo" last="Bonuccelli">Ubaldo Bonuccelli</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Clinica Neurologica, Università di Pisa</s1><s2>Pisa</s2><s3>ITA</s3><sZ>2 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Pisa</wicri:noRegion></affiliation></author><author><name sortKey="Brefel, Christine" sort="Brefel, Christine" uniqKey="Brefel C" first="Christine" last="Brefel">Christine Brefel</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Laboratoire de Pharmacologie Médical et Clinique, INSERM U455</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>3 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Chaudhuri, K Ray" sort="Chaudhuri, K Ray" uniqKey="Chaudhuri K" first="K. Ray" last="Chaudhuri">K. Ray Chaudhuri</name><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Department of Neurology, King's College Hospital</s1><s2>London</s2><s3>GBR</s3><sZ>4 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Colosimo, Carlo" sort="Colosimo, Carlo" uniqKey="Colosimo C" first="Carlo" last="Colosimo">Carlo Colosimo</name><affiliation wicri:level="4"><inist:fA14 i1="05"><s1>Dipartimento di Scienze Neurologiche, Università La Sapienza</s1><s2>Roma</s2><s3>ITA</s3><sZ>5 aut.</sZ></inist:fA14><country>Italie</country><placeName><settlement type="city">Rome</settlement><region nuts="2">Latium</region></placeName><orgName type="university">Université de Rome « La Sapienza »</orgName></affiliation></author><author><name sortKey="Eichhorn, Tobias" sort="Eichhorn, Tobias" uniqKey="Eichhorn T" first="Tobias" last="Eichhorn">Tobias Eichhorn</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Klinik für Neurologie, Zentrum für Nervenheilkunde, Philipps-Universität Marburg</s1><s3>DEU</s3><sZ>6 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Philipps-Universität Marburg</wicri:noRegion><wicri:noRegion>Klinik für Neurologie, Zentrum für Nervenheilkunde, Philipps-Universität Marburg</wicri:noRegion></affiliation></author><author><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Neurology, Beilinson Medical Centre, Sackler Medical School</s1><s2>Tel-Aviv</s2><s3>ISR</s3><sZ>7 aut.</sZ></inist:fA14><country>Israël</country><wicri:noRegion>Tel-Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Pollak, Pierre" sort="Pollak, Pierre" uniqKey="Pollak P" first="Pierre" last="Pollak">Pierre Pollak</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Service de Neurologie, Université J. Fourier</s1><s2>Grenoble</s2><s3>FRA</s3><sZ>8 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Grenoble</settlement></placeName><placeName><settlement type="city">Grenoble</settlement><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region></placeName><orgName type="hospital" n="4">Centre hospitalier universitaire Grenoble Alpes</orgName></affiliation></author><author><name sortKey="Van Laar, Teus" sort="Van Laar, Teus" uniqKey="Van Laar T" first="Teus" last="Van Laar">Teus Van Laar</name><affiliation wicri:level="3"><inist:fA14 i1="09"><s1>Department of Neurology, Leiden University Medical Centre</s1><s2>Leiden</s2><s3>NLD</s3><sZ>9 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Leyde</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Zappia, Mario" sort="Zappia, Mario" uniqKey="Zappia M" first="Mario" last="Zappia">Mario Zappia</name><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Clinica Neurologica, Università di Catanzaro</s1><s2>Catanzaro</s2><s3>ITA</s3><sZ>10 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Catanzaro</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">01-0333009</idno><date when="2001">2001</date><idno type="stanalyst">PASCAL 01-0333009 INIST</idno><idno type="RBID">Pascal:01-0333009</idno><idno type="wicri:Area/PascalFrancis/Corpus">002A25</idno><idno type="wicri:Area/PascalFrancis/Curation">000296</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002A28</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease</title><author><name sortKey="Albanese, Alberto" sort="Albanese, Alberto" uniqKey="Albanese A" first="Alberto" last="Albanese">Alberto Albanese</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Istituto di Neurologia, Università Cattolica, and Istituto Nazionale Neurologico</s1><s2>Milano</s2><s3>ITA</s3><sZ>1 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Milano</wicri:noRegion></affiliation></author><author><name sortKey="Bonuccelli, Ubaldo" sort="Bonuccelli, Ubaldo" uniqKey="Bonuccelli U" first="Ubaldo" last="Bonuccelli">Ubaldo Bonuccelli</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Clinica Neurologica, Università di Pisa</s1><s2>Pisa</s2><s3>ITA</s3><sZ>2 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Pisa</wicri:noRegion></affiliation></author><author><name sortKey="Brefel, Christine" sort="Brefel, Christine" uniqKey="Brefel C" first="Christine" last="Brefel">Christine Brefel</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Laboratoire de Pharmacologie Médical et Clinique, INSERM U455</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>3 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Chaudhuri, K Ray" sort="Chaudhuri, K Ray" uniqKey="Chaudhuri K" first="K. Ray" last="Chaudhuri">K. Ray Chaudhuri</name><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Department of Neurology, King's College Hospital</s1><s2>London</s2><s3>GBR</s3><sZ>4 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Colosimo, Carlo" sort="Colosimo, Carlo" uniqKey="Colosimo C" first="Carlo" last="Colosimo">Carlo Colosimo</name><affiliation wicri:level="4"><inist:fA14 i1="05"><s1>Dipartimento di Scienze Neurologiche, Università La Sapienza</s1><s2>Roma</s2><s3>ITA</s3><sZ>5 aut.</sZ></inist:fA14><country>Italie</country><placeName><settlement type="city">Rome</settlement><region nuts="2">Latium</region></placeName><orgName type="university">Université de Rome « La Sapienza »</orgName></affiliation></author><author><name sortKey="Eichhorn, Tobias" sort="Eichhorn, Tobias" uniqKey="Eichhorn T" first="Tobias" last="Eichhorn">Tobias Eichhorn</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Klinik für Neurologie, Zentrum für Nervenheilkunde, Philipps-Universität Marburg</s1><s3>DEU</s3><sZ>6 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Philipps-Universität Marburg</wicri:noRegion><wicri:noRegion>Klinik für Neurologie, Zentrum für Nervenheilkunde, Philipps-Universität Marburg</wicri:noRegion></affiliation></author><author><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Neurology, Beilinson Medical Centre, Sackler Medical School</s1><s2>Tel-Aviv</s2><s3>ISR</s3><sZ>7 aut.</sZ></inist:fA14><country>Israël</country><wicri:noRegion>Tel-Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Pollak, Pierre" sort="Pollak, Pierre" uniqKey="Pollak P" first="Pierre" last="Pollak">Pierre Pollak</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Service de Neurologie, Université J. Fourier</s1><s2>Grenoble</s2><s3>FRA</s3><sZ>8 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Grenoble</settlement></placeName><placeName><settlement type="city">Grenoble</settlement><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region></placeName><orgName type="hospital" n="4">Centre hospitalier universitaire Grenoble Alpes</orgName></affiliation></author><author><name sortKey="Van Laar, Teus" sort="Van Laar, Teus" uniqKey="Van Laar T" first="Teus" last="Van Laar">Teus Van Laar</name><affiliation wicri:level="3"><inist:fA14 i1="09"><s1>Department of Neurology, Leiden University Medical Centre</s1><s2>Leiden</s2><s3>NLD</s3><sZ>9 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Leyde</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Zappia, Mario" sort="Zappia, Mario" uniqKey="Zappia M" first="Mario" last="Zappia">Mario Zappia</name><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Clinica Neurologica, Università di Catanzaro</s1><s2>Catanzaro</s2><s3>ITA</s3><sZ>10 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Catanzaro</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2001">2001</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term><term>Antiparkinson agent</term><term>Chemotherapy</term><term>Consensus conference</term><term>Diagnosis</term><term>Dopamine agonist</term><term>Dopamine receptor</term><term>Human</term><term>Levodopa</term><term>Parkinson disease</term><term>Pharmacologic test</term><term>Recommendation</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term><term>Epreuve pharmacologique</term><term>Lévodopa</term><term>Antiparkinsonien</term><term>Chimiothérapie</term><term>Apomorphine</term><term>Stimulant dopaminergique</term><term>Agoniste</term><term>Récepteur dopaminergique</term><term>Conférence consensus</term><term>Recommandation</term><term>Diagnostic</term><term>Traitement</term><term>Homme</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Recommandation</term><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Available evidence on the practice of acute pharmacological challenge tests in parkinsonian patients was reviewed by a committee of experts, which achieved a general consensus. The published data deal mainly with the acute administration of levodopa and apomorphine in Parkinson's disease. Such challenge may serve different purposes, e.g., research, diagnosis, or tailoring of treatment. Unique protocols describing the clinical setting and practice parameters are not available. The present paper describes the scientific background and supplies practical guidelines, whenever possible, to perform and evaluate acute challenge tests in parkinsonian syndromes. With the appropriate indication and setting, acute challenge tests are useful in diagnosis and therapy of Parkinson's disease and related disorders.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0></fA01><fA03 i2="1"><s0>Mov. disord.</s0></fA03><fA05><s2>16</s2></fA05><fA06><s2>2</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease</s1></fA08><fA11 i1="01" i2="1"><s1>ALBANESE (Alberto)</s1></fA11><fA11 i1="02" i2="1"><s1>BONUCCELLI (Ubaldo)</s1></fA11><fA11 i1="03" i2="1"><s1>BREFEL (Christine)</s1></fA11><fA11 i1="04" i2="1"><s1>CHAUDHURI (K. Ray)</s1></fA11><fA11 i1="05" i2="1"><s1>COLOSIMO (Carlo)</s1></fA11><fA11 i1="06" i2="1"><s1>EICHHORN (Tobias)</s1></fA11><fA11 i1="07" i2="1"><s1>MELAMED (Eldad)</s1></fA11><fA11 i1="08" i2="1"><s1>POLLAK (Pierre)</s1></fA11><fA11 i1="09" i2="1"><s1>VAN LAAR (Teus)</s1></fA11><fA11 i1="10" i2="1"><s1>ZAPPIA (Mario)</s1></fA11><fA14 i1="01"><s1>Istituto di Neurologia, Università Cattolica, and Istituto Nazionale Neurologico</s1><s2>Milano</s2><s3>ITA</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>Clinica Neurologica, Università di Pisa</s1><s2>Pisa</s2><s3>ITA</s3><sZ>2 aut.</sZ></fA14><fA14 i1="03"><s1>Laboratoire de Pharmacologie Médical et Clinique, INSERM U455</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>3 aut.</sZ></fA14><fA14 i1="04"><s1>Department of Neurology, King's College Hospital</s1><s2>London</s2><s3>GBR</s3><sZ>4 aut.</sZ></fA14><fA14 i1="05"><s1>Dipartimento di Scienze Neurologiche, Università La Sapienza</s1><s2>Roma</s2><s3>ITA</s3><sZ>5 aut.</sZ></fA14><fA14 i1="06"><s1>Klinik für Neurologie, Zentrum für Nervenheilkunde, Philipps-Universität Marburg</s1><s3>DEU</s3><sZ>6 aut.</sZ></fA14><fA14 i1="07"><s1>Department of Neurology, Beilinson Medical Centre, Sackler Medical School</s1><s2>Tel-Aviv</s2><s3>ISR</s3><sZ>7 aut.</sZ></fA14><fA14 i1="08"><s1>Service de Neurologie, Université J. Fourier</s1><s2>Grenoble</s2><s3>FRA</s3><sZ>8 aut.</sZ></fA14><fA14 i1="09"><s1>Department of Neurology, Leiden University Medical Centre</s1><s2>Leiden</s2><s3>NLD</s3><sZ>9 aut.</sZ></fA14><fA14 i1="10"><s1>Clinica Neurologica, Università di Catanzaro</s1><s2>Catanzaro</s2><s3>ITA</s3><sZ>10 aut.</sZ></fA14><fA20><s1>197-201</s1></fA20><fA21><s1>2001</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20953</s2><s5>354000096545190040</s5></fA43><fA44><s0>0000</s0><s1>© 2001 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>45 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>01-0333009</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Movement disorders</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Available evidence on the practice of acute pharmacological challenge tests in parkinsonian patients was reviewed by a committee of experts, which achieved a general consensus. The published data deal mainly with the acute administration of levodopa and apomorphine in Parkinson's disease. Such challenge may serve different purposes, e.g., research, diagnosis, or tailoring of treatment. Unique protocols describing the clinical setting and practice parameters are not available. The present paper describes the scientific background and supplies practical guidelines, whenever possible, to perform and evaluate acute challenge tests in parkinsonian syndromes. With the appropriate indication and setting, acute challenge tests are useful in diagnosis and therapy of Parkinson's disease and related disorders.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17G</s0></fC02><fC02 i1="02" i2="X"><s0>002B02B06</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Epreuve pharmacologique</s0><s5>04</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Pharmacologic test</s0><s5>04</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Prueba farmacológica</s0><s5>04</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Lévodopa</s0><s5>07</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Levodopa</s0><s5>07</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Levodopa</s0><s5>07</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Antiparkinsonien</s0><s5>08</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Antiparkinson agent</s0><s5>08</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Antiparkinsoniano</s0><s5>08</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Chimiothérapie</s0><s5>09</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Chemotherapy</s0><s5>09</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Quimioterapia</s0><s5>09</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Apomorphine</s0><s2>NK</s2><s2>FR</s2><s5>10</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0><s5>11</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Dopamine agonist</s0><s5>11</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0><s5>11</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Agoniste</s0><s5>12</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Agonist</s0><s5>12</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Agonista</s0><s5>12</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Récepteur dopaminergique</s0><s5>13</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Dopamine receptor</s0><s5>13</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Receptor dopaminérgico</s0><s5>13</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Conférence consensus</s0><s5>16</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Consensus conference</s0><s5>16</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Conferencia consensus</s0><s5>16</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Recommandation</s0><s5>17</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Recommendation</s0><s5>17</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Recomendación</s0><s5>17</s5></fC03><fC03 i1="12" i2="X" l="FRE"><s0>Diagnostic</s0><s5>18</s5></fC03><fC03 i1="12" i2="X" l="ENG"><s0>Diagnosis</s0><s5>18</s5></fC03><fC03 i1="12" i2="X" l="SPA"><s0>Diagnóstico</s0><s5>18</s5></fC03><fC03 i1="13" i2="X" l="FRE"><s0>Traitement</s0><s5>19</s5></fC03><fC03 i1="13" i2="X" l="ENG"><s0>Treatment</s0><s5>19</s5></fC03><fC03 i1="13" i2="X" l="SPA"><s0>Tratamiento</s0><s5>19</s5></fC03><fC03 i1="14" i2="X" l="FRE"><s0>Homme</s0><s5>20</s5></fC03><fC03 i1="14" i2="X" l="ENG"><s0>Human</s0><s5>20</s5></fC03><fC03 i1="14" i2="X" l="SPA"><s0>Hombre</s0><s5>20</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>41</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>41</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>41</s5></fC07><fN21><s1>232</s1></fN21></pA></standard></inist><affiliations><list><country><li>Allemagne</li><li>France</li><li>Israël</li><li>Italie</li><li>Pays-Bas</li><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Auvergne-Rhône-Alpes</li><li>Grand Londres</li><li>Hollande-Méridionale</li><li>Latium</li><li>Rhône-Alpes</li></region><settlement><li>Grenoble</li><li>Leyde</li><li>Londres</li><li>Rome</li><li>Toulouse</li></settlement><orgName><li>Centre hospitalier universitaire Grenoble Alpes</li><li>Université de Rome « La Sapienza »</li></orgName></list><tree><country name="Italie"><noRegion><name sortKey="Albanese, Alberto" sort="Albanese, Alberto" uniqKey="Albanese A" first="Alberto" last="Albanese">Alberto Albanese</name></noRegion><name sortKey="Bonuccelli, Ubaldo" sort="Bonuccelli, Ubaldo" uniqKey="Bonuccelli U" first="Ubaldo" last="Bonuccelli">Ubaldo Bonuccelli</name><name sortKey="Colosimo, Carlo" sort="Colosimo, Carlo" uniqKey="Colosimo C" first="Carlo" last="Colosimo">Carlo Colosimo</name><name sortKey="Zappia, Mario" sort="Zappia, Mario" uniqKey="Zappia M" first="Mario" last="Zappia">Mario Zappia</name></country><country name="France"><noRegion><name sortKey="Brefel, Christine" sort="Brefel, Christine" uniqKey="Brefel C" first="Christine" last="Brefel">Christine Brefel</name></noRegion><name sortKey="Pollak, Pierre" sort="Pollak, Pierre" uniqKey="Pollak P" first="Pierre" last="Pollak">Pierre Pollak</name></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Chaudhuri, K Ray" sort="Chaudhuri, K Ray" uniqKey="Chaudhuri K" first="K. Ray" last="Chaudhuri">K. Ray Chaudhuri</name></region></country><country name="Allemagne"><noRegion><name sortKey="Eichhorn, Tobias" sort="Eichhorn, Tobias" uniqKey="Eichhorn T" first="Tobias" last="Eichhorn">Tobias Eichhorn</name></noRegion></country><country name="Israël"><noRegion><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name></noRegion></country><country name="Pays-Bas"><region name="Hollande-Méridionale"><name sortKey="Van Laar, Teus" sort="Van Laar, Teus" uniqKey="Van Laar T" first="Teus" last="Van Laar">Teus Van Laar</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A28 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 002A28 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:01-0333009
|texte= Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |